NCT06746116 - A Study to Evaluate the Use of Durvalumab in Combination With Platinum-based Chemotherapy Followed by Durvalumab With Olaparib as First-line Treatment in Advanced or Recurrent Endometrial Cancer in Spain | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 30, 2024

Primary Completion Date

November 30, 2028

Study Completion Date

November 30, 2028

Conditions

Advanced or Recurrent Endometrial Cancer

Interventions

DRUG

Durvalumab + Chemotherapy phase

Durvalumab (IV) with SoC (carboplatin + paclitaxel chemotherapy: patients should receive at least 4, but preferably 6 cycles) every three weeks.

DRUG

Durvalumab + Olaparib phase

durvalumab (IV) with olaparib (tablets) every four weeks until progression.

Trial Locations (24)

14004

Research Site, Córdoba

15006

Research Site, A Coruña

17007

Research Site, Girona

20014

Research Site, San Sebastián

28034

Research Site, Madrid

28041

Research Site, Madrid

28046

Research Site, Madrid

28807

Research Site, Madrid

29010

Research Site, Málaga

30120

Research Site, El Palmar

31008

Research Site, Pamplona

35016

Research Site, Las Palmas de Gran Canaria

36312

Research Site, Vigo

37007

Research Site, Salamanca

39008

Research Site, Santander

41013

Research Site, Seville

46009

Research Site, Valencia

46010

Research Site, Valencia

46026

Research Site, Valencia

48903

Research Site, Barakaldo

50009

Research Site, Zaragoza

03010

Research Site, Alicante

08035

Research Site, Barcelona

08908

Research Site, L'Hospitalet de Llobregat